Savara Pharmaceuticals

Savara is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions that are inadequately treated with currently available medicines.
 
The company’s lead product, AeroVanc™ (vancomycin hydrochloride inhalation powder), addresses an unmet clinical need in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF).  AeroVanc is an inhaled dry powder form of the antibiotic vancomycin in a capsule-based inhaler designed for convenient self-administration.  Savara has successfully completed a Phase I clinical trial of AeroVanc and is conducting a lung pharmacokinetics clinical study in cystic fibrosis patients with data expected this year.